Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease
- M. Lisanti, P. Scherer, M. Sargiacomo
- BiologyJournal of Cell Biology
- 1 July 1994
Characterization of these complexes by micro-sequencing and immuno- blotting reveals known receptors for modified forms of LDL, multiple GPI-linked proteins, an anion transporter, cytoskeletal elements, and cytoplasmic signaling molecules--including Src-like kinases, hetero- trimeric G-proteins, and three members of the Rap family of small GTPases.
Activation of the adhesive capacity of CR3 on neutrophils by endotoxin: dependence on lipopolysaccharide binding protein and CD14
- S. Wright, R. Ramos, A. Hermanowski‐Vosatka, P. Rockwell, P. Detmers
- Medicine, BiologyJournal of Experimental Medicine
- 1 May 1991
Enhanced activity of CR3 and other members of the CD11/CD18 family underlies many of the known physiological responses of PMN to LPS and may be a central feature of the in vivo responses ofPMN to endotoxin.
11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice
- A. Hermanowski‐Vosatka, J. Balkovec, R. Thieringer
- Biology, MedicineJournal of Experimental Medicine
- 15 August 2005
These data provide the first evidence that pharmacologic inhibition of intracellular GC activation can effectively treat atherosclerosis, the key clinical consequence of metabolic syndrome, in addition to its salutary effect on multiple aspects of the metabolic syndrome itself.
Effects of an 11β‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndrome
- P. Feig, S. Shah, K. Kaufman
- Medicine, ChemistryDiabetes, obesity and metabolism
- 1 June 2011
Aim: We examined the effects of the 11β‐hydroxysteroid dehydrogenase type 1 (HSD1) inhibitor, MK‐0916, on the multiple components of the metabolic syndrome (MetS) in patients with type 2 diabetes…
Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol Lowering
- C. Sparrow, C. Burton, S. Wright
- Biology, MedicineArteriosclerosis, Thrombosis and Vascular Biology
- 1 July 2000
Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension.
- Sukrut Shah, A. Hermanowski‐Vosatka, P. Feig
- MedicineJournal of the American Society of Hypertension…
- 1 May 2011
Induction of 11β-hydroxysteroid dehydrogenase type 1 but not -2 in human aortic smooth muscle cells by inflammatory stimuli
- T. Cai, B. Wong, S. Mundt, R. Thieringer, S. Wright, A. Hermanowski‐Vosatka
- BiologyJournal of Steroid Biochemistry and Molecular…
- 1 May 2001
Expression of the Type I Diabetes-associated Gene LRP5 in Macrophages, Vitamin A System Cells, and the Islets of Langerhans Suggests Multiple Potential Roles in Diabetes
- D. Figueroa, J. Hess, Christopher P. Austin
- Biology, MedicineJournal of Histochemistry and Cytochemistry
- 1 October 2000
An extensive expression analysis of this gene at the mRNA and protein levels in normal human, monkey, and mouse, as well as in non-obese diabetic (NOD) mice, suggests that LRP5 may confer Type 1 diabetes risk by altering the normal functioning of one or more of these regulatory systems.
Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration.
- A. Hermanowski‐Vosatka, S. Mundt, C. P. Whitman
- 4 September 1999
A new biological function is reported for MIF, as an inhibitor of monocyte chemoattractant protein 1- (MCP-1-) induced chemotaxis of human peripheral blood monocytes, and it is found that MIF inhibition ofChemotaxis does not occur at the level of the CC chemokine receptor for M CP-1, CCR2, since MIF does not alter the binding of (125)I-MCP -1 to monocytes.